The Group markets a number of therapeutic pharmaceutical products, including in-licensed and in-house developed products. By the end of September 2008, the Group had seven in-licensed products. with exclusivity in China, including Deanxit, Ursofalk, Stulln, Ganfule and Weimaining, which target anti-depressant, digestion, ophthalmic and oncology markets. The Group's self-developed products include Jinerlun, Liernuo and Shierxing, which contribute to the Group's sales performance. Besides pharmaceuticals, the Group is now producing and selling a patent protected integrated infusion monitoring system for hospital use, comprising of three devices, namely, an infusion pump, an injection pump, and a wireless multi-device infusion supervision system.